Status:

RECRUITING

Fisetin Supplementation for Healthy Aging

Lead Sponsor:

Ove Andersen

Conditions:

Healthy

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. Th...

Detailed Description

The goal of this study is to assess the anti-inflammatory effects, overall health benefits, and the safety of a daily low dose (100 mg) of fisetin in relatively healthy middle-aged and older adults. ...

Eligibility Criteria

Inclusion

  • Middle-aged or older adult (≥50 years),
  • Able to cooperate cognitively,
  • Able to read and understand Danish,

Exclusion

  • Inability or unwillingness to take oral supplements,
  • Chronic or recent (within 30 days) use of other anti-aging supplements,
  • Chronic or recent (within 30 days) treatment with medications having anti-aging effects (e.g., metformin, rapamycin, semaglutide),
  • Chronic or recent (within 30 days) treatment with anti-inflammatory medications,
  • Chronic or recent (within 30 days) treatment with the medications that can interact negatively with fisetin,
  • Recent (within 14 days) vaccination,
  • Treatment with another investigational drug or other intervention within 1 year,
  • Active cancer or current cancer treatment,
  • Unstable or uncontrolled major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer, requiring regular monitoring at the hospital
  • Planned medical and surgical procedures during the study period,
  • Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules,
  • Presence of any condition that the investigator believes would put the participant at risk or would preclude the participant from successfully completing all aspects of the study

Key Trial Info

Start Date :

September 24 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 20 2035

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT07195318

Start Date

September 24 2025

End Date

September 20 2035

Last Update

November 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre

Hvidovre, Denmark, 2650